Company intelligence / Profile preview

Generian Pharmaceuticals

Pittsburgh, PA, United Statesgenerian.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Generian is advancing a pipeline of first-in-class orally available small molecule therapeutics targeting difficult-to-drug proteins. The company has achieved preclinical milestones in collaboration with Astellas/Mitobridge and is preparing IND applications for select programs. No clinical results are available as all programs remain preclinical or at the IND-enabling stage.

Therapeutic areas: OphthalmologyNeurologyImmunologyEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

GT300

Partnerships

Mitobridge, Inc. / Astellas Pharma Inc.: Collaboration and exclusive license agreement to discover/develop novel small molecules for undruggable targets. Potential milestone payments over $180 million plus royalties on sales if successful.

Beyond the preview

Go deeper on Generian Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Generian Pharmaceuticals.

Explore the full profile